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A B S T R A C T
The United States (US) is in the midst of an epidemic of opioid use; however, overdose mortality dis-
proportionately affects certain subgroups. For example, more than half of state prisoners and approximately two-
thirds of county jail detainees report issues with substance use. Overdose is one of the leading causes of mortality 
among individuals released from correctional settings. Even though the criminal justice (CJ) system interacts 
with a disproportionately high number of individuals at risk of opioid use and overdose, few CJ agencies screen 
for opioid use disorder (OUD). Even less provide access to medication assisted treatment (e.g. methadone, bu-
prenorphine, and depot naltrexone), which is one of the most effective tools to combat addiction and lower 
overdose risk. However, there is an opportunity to implement programs across the CJ continuum in colla-
boration with law enforcement, courts, correctional facilities, community service providers, and probation and 
parole. In the current paper, we introduce the concept of a “CJ Continuum of Care for Opioid Users at Risk of 
Overdose”, grounded by the Sequential Intercept Model. We present each step on the CJ Continuum and include 
a general overview and highlight opportunities for: 1) screening for OUD and overdose risk, 2) treatment and/or 
diversion, and 3) overdose prevention and naloxone provision.
1. Introduction
The United States (US) is in the midst of an epidemic of opioid use;
associated overdose deaths have risen at an alarming rate in recent
years. From 2000 to 2014, the rate of opioid-involved overdose deaths
increased by 200% (Rudd et al., 2016). Opioids and opiates—such as
prescription painkillers, heroin, and fentanyl—were responsible for
over 52,404 deaths nationwide in 2015. The number of American lives
lost to opioid overdose each year is comparable to those lost at the peak
of the AIDS epidemic or by the end of the Vietnam War. Over the past
two decades, non-medical prescription opioid use contributed sub-
stantially to rising overdose rates (Calcaterra, Glanz, & Binswanger,
2013; Cerdá et al., 2013; Kenan, Mack, & Paulozzi, 2012). In more
recent years, national initiatives to reduce opioid prescribing have
produced modest declines in the number of prescription opioids dis-
pensed (Dart et al., 2015). However, from 2010 to 2014, the rate of
heroin-involved overdose deaths in the US increased three-fold
(Compton, Jones, & Baldwin, 2016). As persons with opioid use dis-
order shift from non-medical prescription opioid use to heroin, the
epidemic of opioid overdose has been exacerbated by contaminated
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2. The CJ continuum of Care for opioid users at risk of overdose
As originally conceptualized, the Sequential Intercept Model (SIM)
provides a theoretical framework for communities to reduce in-
carceration rates among the mentally ill. The Model flows through a
series of five intercepts; each aims to divert individuals from the tra-
ditional CJ system and into treatment. Necessarily, the SIM, as origin-
ally designed, does not focus on incarceration as a point of inter-
vention—the CJ Continuum of Care for Opioid Users at Risk of
Overdose presented in this paper diverges in this way. In the current
paper, we have adapted the SIM to include five continuum points (see
Fig. 1). Below we present each step on the CJ Continuum and include a
general overview and highlight opportunities for: 1) screening for OUD
and overdose risk, 2) treatment and/or diversion, and 3) overdose
prevention and naloxone provision. Enveloped in each of these cate-
gories are the identification of those with OUD and/or at risk of over-
dose; opportunities for medication assisted treatment; and, finally,
strategies for naloxone provision.
2.1. Law enforcement interactions
State and local police officers work at the gateway of the CJ system.
As first responders, law enforcement officers (LEO) may encounter
opioid users who are actively overdosing, using, or in withdrawal and/
or who are buying, selling, or in possession of opioids. While LEO are
not trained to make clinical assessments or recommendations regarding
an individual's opioid use, they can play an integral role in overdose
reversal and make recommendations for consideration of treatment. In
addition, sheriffs are often elected officials who set the tone for how
their jurisdiction responds to problems rooted in substance use. They
can be powerful messengers in advocating for the expansion of health
promotion and harm reduction interventions that are accessible via the
health and social service systems and not contingent on arrest, prose-
cution, or sentencing.
2.1.1. Screening for OUD and overdose risk and diversion
Law Enforcement Assisted Diversion (LEAD) is a pre-booking di-
version program specifically designed for substance users in the US. The
program was initially established in 2011 in Seattle, Washington, and
offers diversion from arrest into case management based on the offense
type (low level drug and prostitution). LEAD often includes collabora-
tions with community partners to conduct assessments and referral to
substance use treatment, though treatment is not a mandated require-
ment of participation. Importantly, after being stopped by a LEO, the
LEO can screen for LEAD eligibility. If eligible, individuals are referred
to a LEAD case manager for intake into the program. A recent long-
itudinal analysis of program data among 318 participants (203 allo-
cated to the LEAD program and 115 allocated to a control condition)
revealed that LEAD participants had 60% lower odds of arrest at six
months post-program entry and 58% and 39% lower odds of arrest and
being charged with a felony, respectively, at three years post-program
entry (Collins, Lonczak, & Clifasefi, 2017). This preliminary success of
the LEAD program has resulted in additional municipalities across the
US developing LEAD sites in Baltimore, Maryland; Fayetteville, North
Carolina; Santa Fe, New Mexico; Albany, New York; Portland, Oregon;
and Huntington, West Virginia; with even more cities currently in
various stages of program planning and development.
2.1.2. Overdose prevention and education
One of the most significant ways in which LEO have shifted their
focus toward a public health approach to opioid addiction is through
prevention of overdose death. During the past several years, police
departments throughout the US have engaged in overdose education
and training and have begun to carry naloxone to reverse opioid
overdose. LEO in more than 200 law enforcement agencies across the
country now carry naloxone (Davis, Carr, Southwell, & Beletsky, 2015).
Data collected across multiple sites suggest that overdose training and
use of naloxone is viewed favorably by officers and increases knowl-
edge about overdose and confidence in ability to reverse an overdose
event (Green, Zaller, Palacios, et al., 2013; Ray & K, 2015; Wagner,
Bovet, Haynes, et al., 2016). Furthermore, in areas where LEO have
received training in overdose prevention and naloxone administration,
there has been a marked decrease in overdose related mortality (US law
enforcement who carry Naloxone, 2017). A recent analysis of data from
Lorain County, Ohio, over a three-year period documented that a na-
loxone training program among more than 500 police officers from the
county sheriff's office and city jurisdictions resulted in a nearly 80%
survival rate among individuals to whom LEO administered naloxone
during an overdose event (Rando, Broering, Olson, et al., 2015). In
Quincy, Massachusetts, one of the first jurisdictions to approve LEO to
carry naloxone, LEO have reversed more than 200 overdoses since 2010
(Leger, 2014). In North Carolina, the North Carolina Harm Reduction
Coalition (NCHRC) reports that LEO have reversed 403 overdoses as of
February of 2017 in the state (US law enforcement who carry Naloxone,
2017).Fig. 1. The CJ Continuum for Opioid Users at Risk of Overdose.
heroin supplies. Since 2013, illicitly-manufactured fentanyl analogs 
have been combined with or substituted for heroin (Centers for Disease 
Control and Prevention & CDC Health Advisory, 2015). Several states 
have documented increases in fentanyl-related overdose fatalities. From 
2013 to 2014, drugs seized by law enforcement that contained fentanyl 
increased by 426%, and, during that same time period, fentanyl-in-
volved overdose deaths increased by 80% (Gladden, Martinez, & Seth, 
2016).
Opioid use disorder (OUD) and overdose disproportionately affect 
certain subgroups. Approximately 24–36% of all people who are ad-
dicted to heroin pass through US prisons and jails each year (Boutwell 
et al., 2006). Recent research has demonstrated that 63% of individuals 
who are incarcerated in local jails report issues with substance use and 
58% of individuals in state-run criminal justice (CJ) facilities have 
substance dependence (Bronson et al., 2017). Following release from 
incarceration, people experience greatly elevated risk of fatal opioid 
overdose as compared to the general population and to other times 
when they are using (Binswanger et al., 2007, 2011, 2013; Farrell & 
Marsden, 2008; Merrall et al., 2010). A study in Washington State found 
that overdose was the leading cause of death among those who were 
previously incarcerated (Binswanger et al., 2013).
While the CJ system interacts with a disproportionately high 
number of individuals at risk of opioid use and overdose, the current 
paradigm of punishment rather than treatment does not facilitate the 
use of effective and coordinated interventions. Few CJ institutions 
screen for OUD using a validated measure and even less provide access 
to medication assisted treatment (e.g. methadone, buprenorphine, and 
depot naltrexone) (MAT), which is one of the most effective tools to 
combat addiction and lower overdose risk (Miller, Griffin, & Gardner, 
2016; Green et al., 2018). However, there is an opportunity to imple-
ment programs at several points across the CJ system including during: 
1) law enforcement interactions; 2) court hearings (pre-and-post dis-
position); 3) pre-trial detention, jail, and prison; 4) community re-entry 
from jails and prisons; and 5) probation and parole. In the current 
paper, we introduce the concept of a “CJ Continuum of Care for Opioid 
Users at Risk of Overdose” that elucidates opportunities for screening 
and assessment, treatment and/or diversion, and overdose prevention 
among those involved in the CJ system. This continuum of care is based 
on the Sequential Intercept Model developed by Munetz and Griffin 
(Munetz & Griffin, 2006).
court personnel, do not reflect Federal funding requirements for drug
courts or recommendations from the National Association for Drug
Court Professionals and other leading authorities (National Association
of Drug Court Professionals, 2010; U.S.D.O. Justice, 2016). Drug courts
should offer MAT as a treatment option to participants and individuals
prescribed MAT should not be excluded from participation. This may
require training for court personnel and local treatment providers, as
well as legislative and regulatory changes. For example, states should
enact laws that mandate drug courts to offer MAT as a condition for
receiving funding, or establish regulatory agencies to conduct oversight
of drug courts and issue fines to jurisdictions that fail to adhere to best-
practices in addiction medicine. In 2015, New York State passed leg-
islation that forbids drug courts from forcing people off of MAT as a
condition of participation (State of New York 2015–2016, 2015).
2.2.3. Overdose education and prevention
At each stage in this process, court-based stakeholders can play a
role in incorporating overdose education and naloxone distribution into
their activities. At the arraignment stage, many public defense agencies
have social workers on staff who can implement overdose education
and naloxone distribution programs in courtrooms, regardless of a
person's legal disposition. It is critical for staff of any court-based di-
version program to immediately assess a potential client's risk for
overdose, and provide access to overdose education and naloxone for
those reporting or displaying risk factors.
2.3. Incarceration
People are incarcerated and in jails and prisons. Jails are locally
operated short-term facilities for individuals awaiting trial, sentencing,
or serving short sentences (typically for less than a year). Prisons are
run by the state or federal government, and hold individuals serving
longer sentences. As recently incarcerated individuals are at an in-
creased risk of overdose after release, the period of incarceration that
proceeds community reentry is a pivotal intervention point for im-
plementing overdose prevention programs, conducting risk assess-
ments, and providing MAT.
2.3.1. Screening for OUD and overdose risk
Screening and assessment tools have been developed and are uti-
lized to assess for OUD. A necessary and crucial step in addressing OUD
and overdose among those who are incarcerated is to ascertain the
magnitude of the problem. While we have provided examples of op-
portunities to screen individuals for OUD and overdose risk across the
CJ continuum, we recognize that institutional level barriers may im-
pede implementation. For example, many county jails, especially in
rural areas, may lack appropriately trained personnel to screen/assess
for OUD and may also lack confidential space in which to conduct
screenings/assessments. However, jail staff can administer rapid opioid
screening tools, such as the RODS, in only a few minutes and can
partner with community based substance use providers in order to
provide more in-depth clinical assessments, as appropriate.
(Wickersham, Azar, Cannon, Altice, & Springer 2015).
2.3.2. Treatment and/or diversion
Individuals who are incarcerated who are flagged for OUD should
be given a clinical assessment to determine options for MAT in addition
to relevant on-site counseling and recovery supports. Numerous studies
have documented far-reaching benefits to implementing MAT in cor-
rectional populations (Sharma et al., 2016); including post-incarcera-
tion reductions in illicit opioid use (Kinlock et al., 2009; Mattick et al.,
2009), criminal behavior (Deck et al., 2009), mortality and overdose
risk (Degenhardt et al., 2011; Kerr et al., 2007; Green et al., 2018), and
HIV risk behaviors (MacArthur et al., 2012). The World Health Orga-
nization (World Health Organization Dept. of Mental Health Substance
Abuse, W.H.O. and U.N.O.o.D.a.C, 2009) and the National Institute on
2.2. The courts
Criminal courts are underutilized settings for establishing opioid 
treatment and overdose prevention initiatives. Public defenders, judges, 
and managers of court-based diversion programs have an especially 
important role to play. The feasibility of screening defendants for OUD 
and delivering overdose education and naloxone distribution programs 
in court systems depends on the nature of the criminal proceeding and 
its timing in the adjudication process.
2.2.1. Screening for OUD and overdose risk
As a general principle, courts should focus on screening and linking 
people with OUD to treatment in the community as early as possible. 
For example, an arraignment is usually a defendant's first court ap-
pearance that occurs within a few hours or days after an arrest, making 
it an important stage for identifying people with OUD. At arraignment, 
judges make crucial decisions that either result in a defendant being 
released to the community (e.g. dismissal, conditional discharge, or bail 
posted), or being sent to jail (e.g. cannot afford to pay bail, held 
pending a trial, or sentenced to jail following guilty plea). However, the 
fast-paced nature of arraignments and the limited time defense attor-
neys have to meet with their clients makes it extremely difficult for 
lawyers to reliably assess whether their client has OUD and advocate for 
outcomes that mitigate overdose risk. To address this, courts can work 
with police and jails to modify booking procedures that occur between 
arrest and arraignment to screen people for overdose risk and, with 
consent, relay that information to their defense attorneys. For example, 
when a LEO books a person into jail following an arrest, a nurse or other 
staff member usually conduct an medical screening with each person to 
identify any urgent health needs warranting immediate medical atten-
tion (Paris, 2009). Screening for OUD could easily be incorporated into 
this screening.
Once reliable information is collected, legal protocols are needed 
that allow healthcare providers to relay information about a patient's 
overdose risk, with consent, to their defense attorneys before arraign-
ment. Streamlining information about person's substance use treatment 
needs, recent service engagement, and overdose risk before arraign-
ment helps defense lawyers advocate to keep their clients out of jail and 
connect them to treatment in the community as early as possible in the 
adjudication process. In conjunction, to maximize the impact of these 
information sharing strategies, public health professionals should con-
duct educational trainings for judges and prosecutors that convey the 
implications of pre-trial detention for overdose risk among people with 
opioid dependencies.
2.2.2. Treatment and/or diversion
Most diversion programs are court-based, and operate at later stages 
of adjudication (i.e. post-arraignment). These include drug courts and 
other specialized courts that provide people charged with a crime the 
option to participate in mandated treatment as part of a conditional 
plea bargain or sentence alternative to going to jail or prison.
Drug courts have become a fixture in the landscape of CJ systems 
over the past two decades. Today, there are approximately 3,000 drug 
courts in the US (Drug Courts, 2017). Drug courts vary in their will-
ingness and organizational capacity to deliver evidence-based treat-
ments for OUD and overdose prevention (Matusow et al., 2013). Results 
from a recent survey of drug courts across the US demonstrated that 
almost all drug courts had opioid addicted participants, but only 47%
offered buprenorphine or methadone and only 56% offered naltrexone 
(Drug Courts, 2017). Despite the scientific evidence supporting the use 
of MAT, many drug courts continue to enforce strict rules rooted in 
abstinence and zero-tolerance philosophies, which often exclude people 
who use MAT from enrolling. Some courts also impose sanctions or 
terminate enrollment for those who initiate MAT as part of their re-
covery process (Csete & Catania, 2013; Matusow et al., 2013). These 
practices, often determined by the attitudes and opinions of judges and
overdose, and intention to return to opioid use (Brinkley-Rubinstein
et al., 2017). This simple, evidence-based screening for risky opioid use
and overdose should be added to all jail/prison discharge processes and
could be shared with community-based treatment facilities. In addition,
community-based MAT and other substance use treatment providers
should screen for recent incarceration as a part of program intake and
target these individuals for intensive support services.
2.4.2. Treatment and/or diversion
Among people who have successfully initiated or continued MAT
post-release, consideration needs to be given to ensure that effective
connections are being made to community treatment providers.
Research has shown that few people follow up on MAT referrals post-
release (Kinlock et al., 2008). In a set of interviews with people who
had a history of current or past opioid use, Fox et al. found that factors
influencing relapse included (1) exposure to drug use in halfway houses
or shelters, (2) loneliness and isolation, and (3) strained family or in-
terpersonal relationships (Fox et al., 2015). Participants also reported
resistance to MAT and the associated stigmas of treatment; they ex-
pressed a desire to use willpower to avoid dependency and relapse. In
addition, a recent research study among 396 individuals seeking
treatment for OUD indicated that arrest increased the likelihood of
relapse post-treatment (Kopak, Lawson, & Hoffmann, 2018). Accord-
ingly, community re-entry interventions should address contextual ex-
posure to opioid use, psychosocial and interpersonal factors, re-arrest
and re-incarceration, and individual-and-provider-level stigma and at-
titudes toward MAT. Programs that combine MAT with case-manage-
ment services may enhance a client's likelihood of avoiding relapse.
Beyond treatment support, case management services may include
education, housing assistance, employment services, and social support
(Beletsky, 2015; Seal et al., 2007; Wolitski & t.P.S.S. Group, 2006).
2.4.3. Overdose education and prevention
Data suggest that few correctional facilities distribute naloxone to
people re-entering the community (Green et al., 2015). Studies in
Scotland and England (Parmar et al., 2017; Strang, Bird, & Parmar,
2013) have found that the provision of naloxone training and supplies
to people leaving prison significantly reduces post-release overdose
fatality rates. For individuals who return to and/or initiative injection
drug use, it is essential that they have access to clean needles through
needle exchange programs, medical clinics, and/or pharmacies (CDC,
2016). Though still limited in the US, a growing number of correctional
systems in the US are implementing naloxone training and distribution
to people leaving correctional facilities. Facilities with significant
numbers of opioid users should consider implementation of similar
programs to combat post-release overdose. Community-based providers
who screen for incarceration can also provide overdose education at the
point of program entry and provide naloxone.
2.5. Parole and probation
In the US, over 4.5 million people are under the supervision of
probation or parole, often referred to as community corrections.
Probation generally refers to a period during which an individual must
comply with a defined set of conditions in lieu of being detained in a
correctional facility. In some states that use split prison/probation
sentencing, people may continue to be under probation supervision
after serving a jail/prison sentence. While functionally similar to pro-
bation, parole is a system created to supervise people being released
from prison prior to the completion of their sentence. Violations of
probation and parole conditions may result in incarceration or re-in-
carceration. Probation and parole officers are responsible for holding
their clients accountable to these conditions, while also supporting re-
habilitation and client success in the community. Given their frequency
of contact with many justice-involved individuals and their unique role
in the system, probation and parole officers have an integral role to the
Drug Abuse (Abuse, N.I.o.D, 2014) strongly endorse the use of MAT to 
treat opioid use disorder in incarcerated populations; nonetheless, there 
has been little to no implementation or routinization of MAT in US jail 
and prison settings.
In the US, there are over 3200 local and county jails and 1800 state 
and federal prisons, but few correctional facilities offer addiction 
treatment using MAT with methadone, buprenorphine or naltrexone 
(Lee et al., 2015; Vestal, 2016). Among correctional facilities that do 
offer MAT, the majority restrict treatment to persons who are pregnant 
(Nunn et al., 2009) or to those who were engaged in methadone 
treatment prior to incarceration, and it is usually only provided on an 
accelerated 30-day taper protocol (Rich et al., 2015). In the context of 
the current opioid epidemic, there has been some movement toward 
adoption of MAT programs. The Rhode Island Department of Correc-
tions recently implemented the first of its kind comprehensive MAT 
program that allows individuals to initiate or continue, where clinically 
appropriate, on methadone, buprenorphine, or depot naltrexone.
Earlier this year the National Governor's Association (NGA) laun-
ched a “learning lab” where correctional entities that are interested in 
MAT program implementation can learn from more established jur-
isdictions. The initiative included North Carolina, Alaska, Indiana, 
Kansas, Minnesota, New Jersey, Virginia, and Washington. 
Participation in the NGA project includes developing and executing 
short-term action plans to address overdose risk and opioid addiction in 
prisons. Continued adoption of MAT programs in correctional settings 
will require dissemination of implementation best practices, mentor-
ship from jurisdictions who have long had MAT programs in place, and 
research related to contextual and institutional factors that may impede 
(e.g. correctional attitudes toward MAT) or facilitate (buy-in from key 
policy makers) success of MAT in closed settings.
2.3.3. Overdose education and prevention
Overdose prevention education programs should be provided in jails 
and prisons, with special attention paid to the limitations that various 
types of correctional facilities may have in place. These overdose pre-
vention programs should provide information for people who are in-
carcerated related to: how to identify signs of a possible overdose, the 
risk factors for overdose, the policies and laws in place that are relevant 
(e.g. Good Samaritan Laws), where to get services (e.g. syringe ex-
change) in the community and the medical risks associated with in-
jection drug use (e.g. hepatitis C, HIV). In addition, naloxone should be 
available in correctional facilities to medical and correctional staff 
members to use in an emergency. A new innovation called a 
“NaloxBox”, similar to defibrillator boxes, that are often available in 
public spaces, could be used in correctional facilities (NaloxBox, n.d.). 
Several NaloxBoxes could be placed strategically in various areas (e.g. 
medical clinic, intake), so officers and staff can have quick access to 
naloxone in the event of an overdose.
2.4. Community re-entry
Studies have shown that people with OUD not only experience ad-
verse consequences during incarceration, but also have poorer drug-
related outcomes post-release during community re-entry (Prendergast, 
2009). The immediate post-release period is a time of extreme overdose 
risk due to loss of opioid tolerance during incarceration, thereby in-
creasing risk of fatal and non-fatal overdose. Providing people with 
OUD access to treatment and prevention services during community re-
entry is essential.
2.4.1. Screening for OUD and overdose
To our knowledge, no overdose risk indexes exist to evaluate an 
individual's risk of opioid overdose post-release. An overdose risk index 
should be developed that considers community-based risks and in-
dividual and institutional features, including lack of social support, fi-
nancial deprivation, exposure/access to drugs, homelessness, history of
3. Discussion
Given the high prevalence of OUD among CJ involved populations
and their extreme risk for opioid-related overdose, there is a critical
need to bolster efforts to identify, treat, and prevent overdose. The SIM
is a useful framework that we have used to illuminate each point along
the CJ continuum (i.e. law enforcement, court, incarceration, re-entry,
probation and parole). Each intercept presents an opportunity to im-
prove outcomes for opioid users by identifying those at risk, promoting
treatment, preventing overdose, and potentially assuaging the collateral
consequences of CJ involvement. However, in order to fully take ad-
vantage of opportunities to intervene, there are numerous logistical,
policy and resource related challenges that must be considered.
Correctional, community, and individual attitudes related to MAT must
be researched and effective training and strategies developed to over-
come MAT stigma, such as educating CJ staff about the relevant health
and CJ-related (e.g. lower rates of re-incarceration) benefits (Miller,
Miller, & Barnes, 2016). In addition, at the local level, political will may
restrict widespread implementation of OUD and overdose programs for
CJ populations. Therefore, guidance that aids in how to gradually adopt
OUD-related programs in challenging CJ environments should be de-
veloped. Just as programs at each step of the continuum require ad-
justment to fit each individual environment (e.g. a screening tool that is
best suited for jails may not be appropriate for probation and parole
settings), consideration of community and regional contexts is im-
perative. For instance, a state like Rhode Island wherein the Depart-
ment of Corrections has jurisdiction over all incarcerated persons in jail
and prison cannot be compared to a state like North Carolina that has a
state prison system and 100 separate county jails. In the same way,
what is possible in a rural, under-resourced county, will not always be
comparable to what can be implemented in some big, urban environ-
ments.
In order to ensure access to MAT and other support services, ap-
propriate resources and funding need to be allocated to all CJ-related
agencies and community based treatment providers who serve CJ in-
volved individuals. With the current attention to the national opioid
epidemic, there is a tremendous opportunity to direct resources where
they are most needed to successfully stem the tide of opioid addiction
and overdose. With the passage of the 21st Century Cures Act in 2017,
Congress demonstrated a commitment to funding MAT for OUD.
However, more resources need to be directed specifically to institutions
and agencies within the CJ system, as these entities interact with a high
proportion of individuals with OUD and can have a tremendous impact
on treating OUD and preventing opioid overdose mortality. In addition,
dedicated funding needs to be directed toward rigorous evaluation of
any new MAT initiatives in correctional settings in order to determine
best practices and a blueprint for future use. However, we acknowledge
that in CJ settings there may be realistic challenges to opioid-relevant
program implementation. For instance, funding allocations can be un-
predictable and change from year to year. In addition, CJ systems'
healthcare costs are already high as people who are incarcerated have a
disproportionately high burden of disease. For law enforcement agen-
cies, the cost of naloxone may be prohibitive leading to an inability to
keep an adequate supply on hand at all times. Finally, it must be noted
that practical concerns related to contagion health problems must also
be considered. Law enforcement officers or other CJ entities could come
into contact with very powerful residual fentanyl powder when re-
sponding to an overdose underscoring the need to address public health
and officer safety needs in any comprehensive CJ relevant program to
combot opioid use or overdose risk.
Despite these issues, the public health community should continue
to advocate for additional resources to treat opioid addiction and its
related consequences in the CJ system. In particular, more can be done
to reduce the costs associated with naloxone, such as rate negotiations
between states. The recently released report from the President's
Commission on Combatting Drug Addiction and the Opioid Crisis, ex-
plicitly calls for increased federal resources to expand access to both
MAT and naloxone, including within the CJ system. The public health
community has an obligation to continue to advocate for federal, state,
and local resources be directed toward evidence-based addiction pre-
vention, treatment, and recovery services within the CJ system and
across the country as a whole.
One important, final consideration is that focusing on the CJ system
as a site of intervention may have the unintended consequences of
extending the reach of the system itself. For example, programs that
rely on intense supervision and are tied to CJ outcomes (e.g., probation
conditions or court mandates) have the potential to lead to harsher
punishment for someone battling addiction and prone to relapse. The
SIM, the framework which informs this paper, was initially con-
ceptualized to identify opportunities to provide clinically appropriate
play in identifying individuals with OUD, supporting treatment, and 
preventing overdose.
2.5.1. Screening for OUD and overdose
While some probation and parole officers may have access to in-
formation about clients' opioid use histories, many may need to do an 
initial OUD screening. Probation officers should be trained to use evi-
dence-based screening tools that screen for opioid use disorder, and 
have a screening protocol. All community corrections staff will need 
knowledge of available community treatment resources, and may for-
mally partner with community-based treatment providers to assist with 
further assessment and to develop treatment plans.
2.5.2. Treatment and/or diversion
Supporting clients with OUD may require taking an approach to 
recovery that does not conform to a jurisdiction's existing community 
corrections framework. SAMHSA guidance reflects the need for a 
nuanced approach to relapse within a community corrections context, 
stating that CJ agency staff must work collaboratively with providers to 
develop a “range of responses” to relapse, and appropriate graduated 
sanctions. SAMHSA best practices stress the importance of treating re-
lapse as part of the recovery process, as opposed to a personal failure, 
and an opportunity to strengthen the recovery support being provided 
by CJ agency staff (Substance Abuse and Mental Health Services 
Administration, 2005).
When it comes to treatment, it is essential that probation and parole 
officers support the treatment plan developed by a client's treatment 
provider. This includes supporting use of all types of MAT for OUD, as 
prescribed by a medical provider. While negative personal beliefs about 
MAT among community corrections officers present considerable bar-
riers to encouraging the use of this evidence-based treatment for people 
on probation and parole, establishing strong communication and part-
nerships with community treatment providers can change staff per-
ceptions and increase intent to refer to treatment (Friedmann et al., 
2012; Friedmann et al., 2015).
2.5.3. Overdose education and prevention
Probation and parole staff should receive training in how and when 
to administer naloxone, and have on-site naloxone access (American 
Society of Addiction Medicine, 2016). In 2015, the Pennsylvania Board 
of Probation and Parole trained field supervision staff in recognizing the 
signs of an overdose as well as naloxone administration and provided 
each Board office with a naloxone kit (Pennsylvania Board of Probation 
and Parole, 2015). A true harm reduction approach would use proba-
tion and parole as a site for naloxone distribution, and community 
corrections agencies should consider their offices' potential to partici-
pate more aggressively in overdose prevention. States can also en-
courage overdose prevention by extending Good Samaritan law-
s—which protect individuals who may be using or holding drugs or 
drug paraphernalia from prosecution when they report an overdose—to 
include individuals on probation and parole.
4. Conclusion
CJ involved individuals are at increased risk of overdose; however,
the CJ system's traditional orientation to punishment rather than public
health has resulted in a dearth of treatment options. Herein, we have
provided specific guidance, on each point of the CJ continuum, to op-
timize implementation of screening, treatment/diversion, and overdose
education and naloxone provision programs. While we acknowledge
the existence of barriers such as cost, attitudes toward MAT, and local
and facility level capacity, CJ-based addiction and overdose initiatives
are necessary to address the current opioid epidemic.
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